Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Patent
1995-06-07
2000-11-14
Moezie, Minna
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
A61K 3159
Patent
active
061470643
ABSTRACT:
Method of treating psoriasis by administering orally a 1.alpha.-hydroxyprevitamin D. This previtamin D form treats psoriasis without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms. The 1.alpha.-hydroxyprevitamin is compounded into a pharmaceutical composition in combination with a pharmaceutically acceptable excipient.
REFERENCES:
patent: 2216719 (1940-10-01), Boer
patent: 2434015 (1948-01-01), Rosenberg et al.
patent: 4230701 (1980-10-01), Holick et al.
patent: 4335120 (1982-06-01), Holick et al.
patent: 4505906 (1985-03-01), DeLuca et al.
patent: 4539153 (1985-09-01), Vandewalle et al.
patent: 4728643 (1988-03-01), Holick et al.
patent: 5013728 (1991-05-01), Grodberg
J. Hosomi et al, Endocrinology, "Regulation of Terminal Differentiation of Cultured Mouse Epidermal Cells by 1.alpha.,25-Dihydroxyvitamin D.sub.3," vol. 113 (1983) pp. 1950-1957.
E. L. Smith et al., The Journal of Investigative Dermatology, "Effect of 1.alpha.,25-Dihydroxyvitamin D.sub.3 on the Morphologic and Biochemical Differentiation of Cultured Human Epidermal Keratinocytes Grown in Serum-Free Conditions," vol. 86 (1986) pp. 709-714.
M.F. Holick, Bone and Mineral Research/7,"Vitamin D and the skin: photobiology, physiology and therapeutic efficacy for psoriasis", Ed. Johan N.M. Heersche and John A. Kanis, Elsevier Science Publishers B.V. (Biomedical Division), New York, NY, 1990, pp. 313-366.
Harrison's Principles of Internal Medicine: Part Eleven, "Disorders of Bone & Mineral Metabolism," Chapter 335, E. Braunwald et al., (eds.) McGraw-Hill, New York (1987) pp. 1860-1865.
M. L. Curtin and W. H. Okamura, J. Am. Chem. Soc., vol. 113 (1991) pp 6958-6966.
Transactions of the Association of American Physicians, vol. XCII, 1979, pp. 54-63, M. F. Holick, S. C. McNeill, J. A. MacLaughlin, S. A. Holick, M. B. Clark and J. T. Potts, Jr., "Physiologic Implications of the Formation of Previtamin D in Skin".
Chemical Abstracts, vol. 110, No. 10, 1989, Columbus, Ohio, Abstract No. 84136v, M. Takahashi, H. Mochizuki, "Enteric-Soluble Capsule Base Composed of Poly(Ethylene Glycol) or Its Substitutes and Cellulose Acetate Phthalate or Hydroxypropyl Methyl Cellulose Phthalate".
Teijin Limited, JP 59-10562, Jan. 20, 1984 (English Translation).
Bishop Charles W.
Knutson Joyce C.
Valliere Charles R.
Bone Care International, Inc.
Meier Linda Blair
Moezie Minna
Wang Shengjun
Welch Teresa J.
LandOfFree
Oral 1.alpha.-hydroxyprevitamin D in composition and method for does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral 1.alpha.-hydroxyprevitamin D in composition and method for , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral 1.alpha.-hydroxyprevitamin D in composition and method for will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065576